Loading…
Loading…
BIAF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BIAF and 80,000+ other tickers.
See exactly how BIAF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BIAF and 80,000+ other tickers.
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies will effect a 1-for-15 reverse split of its common stock at the opening of trading on Nasdaq on August 24, 2026.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AvMEDICAL--bioAffinity Technologies enters distribution agreement with AvMEDICAL to expand CyPath Lung sales reach and access to government healthcare systems.
JERSEY CITY, N.J., Aug. 14, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that it has closed its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of pre-funded warrants to purchase an aggregate of 8,462,027 shares of common stock.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies announces closing of $4M private placement offering.
JERSEY CITY, N.J., , Aug. 13, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that it has entered into a securities purchase agreement with an institutional investor to sell 8,462,027 shares of common stock (or pre-funded warrants in lieu thereof), together with two warrants to purchase up to an aggregate 16,924,054 shares of common stock, in a private placement offering priced at-the-market under Nasdaq rules.